Sherbrooke team patents GlioTrap brain cancer treatment after promising preclinical cures
Sherbrooke researchers patent GlioTrap, a gel-based brain cancer treatment showing strong preclinical results; the team aims to begin human trials in about two years.
Sherbrooke researchers patent GlioTrap
Dr. David Fortin, a neuro-oncologist and neurosurgeon at the Centre hospitalier universitaire de Sherbrooke (CHUS), and his laboratory have secured a patent for a new intervention called GlioTrap. The invention, developed over more than a decade by Fortin’s team and led in part by research professional Gabriel Charest, targets brain tumours that are notoriously difficult to treat. GlioTrap is being presented as a localized strategy placed in the surgical cavity after tumour resection to capture and destroy remaining malignant cells.
The team emphasizes that the device is intended to work where traditional approaches have limitations, notably the blood-brain barrier and the diffuse spread of tumour cells. The research group includes graduate researcher Laurence Déry and collaborators at the Université de Sherbrooke and the University of Victoria. The project is moving from promising laboratory findings toward regulatory and clinical planning.
Design and mechanism of the gel-based treatment
GlioTrap is built around a degradable gel matrix that is deposited into the cavity left after surgical removal of a brain tumour. The gel releases a combination of three active elements: a sustained-release chemotherapy agent, a short-range radioisotope for localized radiation, and an innovative chemo-attractant molecule. Together, the components are intended to create a high-concentration therapeutic zone around the resection cavity and to lure scattered tumour cells back into that zone.
The chemo-attractant functions like a molecular “magnet,” according to the team, drawing migratory malignant cells toward the gel where they are exposed to cytotoxic chemotherapy and targeted radiation. This multi-pronged local approach is designed to address two persistent problems in neuro-oncology: residual microscopic disease after surgery and the difficulty systemic drugs face crossing the blood-brain barrier. By concentrating therapy at the surgical margin, GlioTrap aims to reduce systemic exposure while increasing local tumour control.
Preclinical trials show cures in rats
In preclinical studies conducted on rodent models, the GlioTrap approach produced results the team describes as unprecedented. In the reported trial, roughly half of treated animals experienced complete remission and longer-term survival, while the remainder showed extended survival compared with controls. Investigators said none of the animals treated with the device experienced premature treatment-related deaths in those experiments.
Researchers caution that animal success does not guarantee human efficacy, noting historic examples where spectacular preclinical outcomes did not translate to patients. Still, the results have galvanized the team, and project lead Gabriel Charest described the strategy of attacking the tumour on several fronts as vindicated by the early data. Graduate student Laurence Déry said the progress reflects years of effort and collaborative work across physics, radiobiology and bioengineering disciplines.
Funding and timeline for human trials
The research team plans to launch a clinical study and believes it can begin human trials in about two years, pending regulatory approvals and the necessary financing. Investigators say financing is a central challenge because glioblastoma and other aggressive brain tumours have relatively low incidence, which can make it harder to attract large-scale funding compared with cancers that affect larger patient populations. The group estimates glioblastoma affects roughly 1,500 people annually, a figure they say contributes to fundraising hurdles.
The team is preparing the manufacturing, safety and regulatory documentation required for first-in-human evaluation, and is seeking support from government agencies, foundations and potential industry partners. Clinical-scale production will also require adjustments to the device composition and supply chain, particularly for the radioisotope component, which has regulatory and logistical constraints.
Manufacturing limits and collaborative solutions
One practical obstacle the researchers identified is the short half-life of the radioisotope used in the current GlioTrap formulation. That property complicates transport and large-scale distribution because the isotope must be produced close to the site of use or deployed quickly after manufacture. To address this, the team is exploring alternative isotopes, production partnerships and formulation tweaks that could lengthen functional viability or allow regional distribution.
The project benefits from collaborations that already supply key elements: Professor Brigitte Guérin at the Université de Sherbrooke supports radioisotope production, and bioengineer Professor Mohsen Akbari at the University of Victoria provided the base gel vehicle used in the experiments. The investigators say those partnerships will be central to adapting the product for clinical manufacture and to convincing funders that the approach can be scaled without compromising safety or efficacy.
The group also notes the possibility of combining GlioTrap with other local or systemic strategies the Sherbrooke team has developed, including targeted intra-arterial chemotherapy, which previously extended median survival in selected patients. Combining modalities could enhance outcomes, but will increase complexity for regulatory review and trial design.
The research team frames GlioTrap as a local, multimodal strategy intended to close the therapeutic gap left after surgery by physically trapping migratory tumour cells and exposing them to concentrated therapy. While preclinical results are encouraging, the investigators stress caution and methodical progression through regulatory safety steps. If clinical studies confirm the early findings, GlioTrap could represent a new direction in treating aggressive brain tumours by turning the post-surgical cavity from a source of recurrence into a controlled therapeutic sink.
